Article Text

other Versions

PDF
Ovarian cancer screening: could you recommend it? No
  1. Juan Gérvas
  1. Avda Alfonso XIII, Madrid, Spain
  1. Correspondence to : Dr Juan Gérvas
    , Avda Alfonso XIII, 19, Madrid 28002, Spain; jjgervas{at}gmail.com

Extract

Last December, The Lancet published the final results of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The summary of the study, distributed in advance, was misleading and the exaggeration was translated in news all over the world. This author reviewed the results and highlights that the UKCTOCS is just one more randomised controlled trial demonstrating that screening reduces neither ovarian cancer-specific mortality nor all-cause mortality.

Statistics from Altmetric.com

Extract

Last December, The Lancet published the final results of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The summary of the study, distributed in advance, was misleading and the exaggeration was translated in news all over the world. This author reviewed the results and highlights that the UKCTOCS is just one more randomised controlled trial demonstrating that screening reduces neither ovarian cancer-specific mortality nor all-cause mortality.

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles